Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Drop in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 6,000 shares, a drop of 80.0% from the February 28th total of 30,000 shares. Approximately 1.1% of the shares of the stock are short sold. Based on an average daily volume of 82,900 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bluejay Diagnostics stock. Anson Funds Management LP raised its stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) by 359.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 319,280 shares of the company’s stock after acquiring an additional 249,770 shares during the quarter. Anson Funds Management LP owned about 1.93% of Bluejay Diagnostics worth $41,000 as of its most recent filing with the Securities and Exchange Commission. 18.47% of the stock is currently owned by institutional investors and hedge funds.

Bluejay Diagnostics Stock Performance

Shares of BJDX opened at $3.73 on Thursday. The company has a market cap of $2.06 million, a price-to-earnings ratio of 0.00 and a beta of 0.38. The stock has a fifty day moving average price of $3.82 and a two-hundred day moving average price of $4.59. Bluejay Diagnostics has a 52-week low of $3.03 and a 52-week high of $323.92.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.